Lupin Pharmaceuticals Inc. recalls Ganirelix Acetate Injection
- Published
- 17 Dec 2025
- Units affected
- 32736 vials
- Agency
- FDA
- Country
- United States
The hazard
Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01
- Brand / company
- Lupin Pharmaceuticals Inc.
- Codes / lots
- Lot #: WB00006, Exp 12/31/2026
- Distribution
- FL, MA, MI & OH
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 17 Dec 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.